Vorinostat and romidepsin are FDA-approved HDAC inhibitors for the treatment of refractory cutaneous T cell lymphoma (CTCL), and there are many others currently under different stages of clinical assessment, most of them focused on hematological malignancies [138]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.